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ABSTRACT
Little information is available on the clinical characteristics of infectious complications that occur in the early
period after reduced-intensity stem cell transplantation (RIST). We retrospectively investigated the clinical
features of neutropenic fever and infectious episodes within 30 days after RIST in 76 patients who had received
fluoroquinolones as part of their antibacterial prophylaxis. Preparative regimens included cladribine 0.66
mg/kg or fludarabine 180 mg/m2 plus busulfan 8 mg/kg. All but 1 patient survived 30 days after transplantation,
and 75 patients (99%) became neutropenic within a median duration of 9 days. Neutropenic fever was observed
in 29 patients (38%), and bacterial infection was confirmed in 15 (20%) of these, including bacteremia (n 13),
bacteremia plus pneumonia (n  1), and urinary tract infection (n  1). The causative organisms were
gram-positive (n  9) and gram-negative organisms (n  7), with a mortality rate of 6%. Neither viral nor
fungal infection was documented. Multivariate analysis showed that the presence of neutropenia at the
initiation of preparative regimens was an independent risk factor for subsequent documented bacterial
infections (P  .026; 95% confidence interval, 1.25-35.1). We conclude that neutropenic fever and bacteremia
remain common complications in RIST.
© 2004 American Society for Blood and Marrow Transplantation
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oNTRODUCTION
Allogeneic stem cell transplantation (allo-SCT) is
promising strategy for patients with various malig-
ant diseases that do not respond to conventional
reatments. Although a graft-versus-tumor effect in-
uced by allo-SCT [1-4] is beneﬁcial in selected pa-
ient populations, increased regimen-related toxicity
RRT) and treatment-related mortality prevent the
ider application of allo-SCT to older patients or
hose who have organ dysfunctions. Recently, a new
trategy for transplantation by using a reduced-inten-
ity or nonmyeloablative regimen has been developed o
B&MTo reduce RRT while preserving a graft-versus-tumor
ffect [5-7]. Although preliminary data seem attrac-
ive, widely acceptable regimens and indications for
his strategy have not yet been established. At present,
everal preparative regimens have been reported in
educed-intensity SCT (RIST), with a wide variation
n the intensity of immunosuppression and myeloab-
ation [5,6,8,9].
Bacterial infection is a major cause of morbidity
nd mortality in neutropenic patients after cancer che-
otherapy [10]. It has been reported that at least half
f febrile neutropenic patients have an established or
ccult undiagnosed infection and that at least one ﬁfth
65
o
a
e
[
p
a
i
h
H
n
i
t
f
t
a
H
i
P
E
u
b
b
t
m
f
D
P
W
T
p
l
h
p
w
o
d
P
m
d
ﬂ
4
r
(
y
h
G
c
P
a
p
p
S
a
c
p
o
o
i
f
[
i
p
c
E


c
c
s
t
a
D
c
t
n
T
A
S
U
R
S
M
P
C
*
†
‡
A. Hori et al.
6f patients with neutrophil counts of 0.1  109/L
cquire bacteremia [10]. Because RIST provides early
ngraftment compared with conventional allo-SCT
6], it can be expected that the incidence of neutro-
enic fever and bacterial infections in the early period
fter transplantation may decrease after RIST. The
ncidence of bacterial infection during the early period
as been reported to range from 0% to 15% [6,11-13].
owever, all of these studies analyzed data from small
umbers of patients who received different condition-
ng regimens or antimicrobial prophylaxis. Moreover,
he deﬁnition of febrile neutropenia or bacterial in-
ection was generally not clear. Thus, we retrospec-
ively investigated the incidence of neutropenic fever
nd infectious episodes within 30 days of RIST from
LA-identical sibling donors and evaluated their clin-
cal signiﬁcance.
ATIENTS AND METHODS
ligibility Criteria
From September 1999 to May 2002, 76 patients
nderwent RIST. It was thought that they would not
e able to tolerate conventional myeloablative SCT
ecause of age, organ dysfunction, or heavy prior
reatment. Donor eligibility required an HLA-
atched sibling donor determined by serologic typing
or HLA-A and -B and molecular typing for HLA-
R.
atient Characteristics
The patients’ characteristics are shown in Table 1.
e divided the risk of transplantation into 2 groups.
he low-risk group included acute myeloid or lym-
hoid leukemia in ﬁrst or second remission, malignant
ymphoma in ﬁrst or second remission, nonmalignant
ematologic disorders, and solid tumors. The other
atients were considered to have high-risk diseases,
hich indicates that patients had a smaller possibility
f transplantation success in curing the underlying
isease.
reparative Regimens and Clinical Management
Twenty-three patients received cladribine 0.11
g/kg on days 8 to 3 and busulfan 4 mg/kg on
ays 6 and 5 [7]. Fifty-three patients received
udarabine 30 mg/m2 on days 8 to 3 and busulfan
mg/kg on days 6 and 5. Forty-one patients
eceived additional rabbit antithymocyte globulin
ATG) 2.5 mg/kg for 2 or 4 consecutive days. Meth-
lprednisolone 0.5 mg/kg was administered every 6
ours for 2 or 4 days in those who received ATG.
raft-versus-host disease (GVHD) prophylaxis was
yclosporine alone, which was started on day 1.
atients were treated in reverse isolation in a laminar
irﬂow–equipped room. All of the patients received t
6rophylaxis with trimethoprim/sulfamethoxazole or
entamidine against Pneumocystis carinii infection.
eventy-one patients received oral ﬂuoroquinolones
s antibacterial prophylaxis. These antibiotics were
ontinued until engraftment or initiation of the em-
iric administration of intravenous antibiotics. The
ther 5 patients received intravenous administration
f other antibiotics from the initiation of condition-
ng. The patients received ﬂuconazole and acyclovir
or fungal and herpes virus prophylaxis, respectively
14,15].
Granulocyte colony-stimulating factor was admin-
stered intravenously at 5 g/kg/d from day 6 of trans-
lantation until the patient’s absolute neutrophil
ount became 0.5  109/L for 2 consecutive days.
ngraftment was deﬁned as a white blood cell count of
1.0  109/L with an absolute neutrophil count of
0.5  109/L for 3 consecutive days and a platelet
ount of20 109/L, without transfusion. Acute and
hronic GVHD were graded according to the consen-
us criteria [16,17]. When patients developed grade II
o IV acute GVHD, we initiated methylprednisolone
t 2 mg/kg/d in addition to cyclosporine.
iagnosis and Definition of Infections
We deﬁned neutropenia as peripheral neutrophil
ounts 0.5  109/L and fever as a single axillar
emperature of 38.3°C. Fever that occurred during
eutropenia was deﬁned as neutropenic fever and was
able 1. Patient Characteristics
Variable Data
ge, y, median (range) 50 (4-67)
ex (male/female) 51/25
nderlying disease
Acute myeloblastic leukemia 20
Acute lymphoblastic leukemia 2
Chronic myelocytic leukemia 5
Myelodysplastic syndrome 9
Malignant lymphoma 16
Solid tumors* 18
Others 6
isk of transplantation (high/low)† 31/45
tem cells (blood/marrow) 76/0
edian number of transfused CD34† cells
 106 cells/kg, median (range) 3.8 (1.6-8.3)
rophylactic antibiotics (fluoroquinolone/others) 71/5
atheters (central/peripheral) 71/21‡
All the patients with solid tumors had documented progressive
lesions despite prior therapy.
Risk of transplantation was divided into 2 groups: the low-risk
group was deﬁned as acute myeloid or lymphoid leukemia in
ﬁrst or second remission, malignant lymphoma in ﬁrst or second
remission, nonmalignant hematologic disorders, and solid tu-
mors; the other patients were deﬁned as having high-risk dis-
eases.
Both peripheral and central lines were inserted in 16 patients.reated as reported previously [10]. “Effective intrave-
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Neutropenic Fever after Reduced-Intensity SCT
Bous antibiotics” was deﬁned as a response evidenced
y decreasing fever to 38°C within 72 hours of the
nitiation of antibiotics [10]. When febrile episodes
ccurred, we obtained more than 2 blood cultures
fter swabbing the skin or catheter hub with 10%
ovidone-iodine. When central venous catheters were
laced, samples for blood culture were drawn through
hese lines. When these samples tested positive, we
epeated blood sampling by vein puncture. When pa-
ients had received more than 0.5 mg/kg corticoste-
oid, we obtained more than 2 blood cultures in the
ame manner at least once a week [18]. Blood stream
nfection must have met at least 1 of the following
riteria [19]. Bacteremia was deﬁned as the condition
escribed in criterion 2.
. Criterion 1: patient has a recognized pathogen cul-
tured from 1 or more blood cultures, and the or-
ganism cultured from blood is not related to an
infection at another site.
. Criterion 2: patient has at least 1 clinical symptom,
such as temperature 38°C, chills, or hypotension
(systolic blood pressure 90 mm Hg), and at least
1 of the following:
a. Common skin contaminant such as diphthe-
roids, Bacillus species, Propionibacterium species,
coagulase-negative staphylococci, or micrococci
cultured from 2 or more blood cultures drawn
on separate occasions.
b. Common skin contaminant such as diphthe-
roids, Bacillus species, Propionibacterium species,
coagulase-negative staphylococci, and micro-
cocci cultured from at least 1 blood culture from
a patient with an intravascular line, and the
physicians have instituted appropriate antimi-
crobial therapy.
When febrile patients presented (1) an erythema-
ous rash involving25% of the body surface that was
ot clearly attributable to medication or (2) noncar-
iogenic pulmonary edema without an identiﬁable in-
ectious etiology during early neutrophil recovery, the
ever was diagnosed as engraftment syndrome [20].
evers associated with GVHD, administration of
TG, and primary malignancies were diagnosed on
he basis of a clearly documented clinical history and
hysical examination, without a direct conﬁrmation of
nfections as described previously.
nd Points and Statistical Analysis
The aims of this study were to determine the
ncidence of neutropenia and neutropenic fever, to
nvestigate the incidence and clinical features of bac-
erial infection early after RIST, and to identify their
isk factors. A univariate analysis with the Fisher exact
est and the Mann-Whitney test was performed to
dentify risk factors for neutropenic fever and bacte-
emia. These variables included age, primary disease d
B&MTnd risk of transplantation, use of ATG, presence of
eutropenia at day 11, nadir and duration of neu-
ropenia, presence of a neutrophil count 0.1 
09/L at any time between day 11 and day 30 after
IST, use of corticosteroids except for prophylactic
se during ATG administration, and diarrhea within
0 days after transplantation. The level of signiﬁcance
as set at P  .05. A multivariate analysis with a
ultiple logistic regression analysis was then added
or the appropriate variables. Factors with a P value of
.25 in the univariate analysis, except for those that
ere considered to be strongly associated with an-
ther variables, were entered into the multiple logistic
egression analysis. The overall survival of patients
ho developed a neutropenic fever was compared
ith that of patients without the presence of neutro-
enic fever by a Kaplan-Meier curve and the log-rank
est. Similarly, the overall survival of patients who
eveloped bacteremia within the ﬁrst 30 days after
IST was compared with that of patients without
acteremia. P values.05 were considered signiﬁcant.
ESULTS
eutropenia, Engraftment, and GVHD
Except for a patient who died of methicillin-resis-
ant Staphylococcus aureus (MRSA) septicemia, all of the
atients survived 30 days after RIST. Neutropenia was
bserved in 75 patients (99%), with a median duration
f 9 days (range, 0-32 days). One patient developed
rimary graft failure, but the remaining 74 patients
chieved sustained engraftment with a median time of
1 days after transplantation (range, 6-24 days). No
atient required donor lymphocyte infusion to achieve
omplete donor chimerism. This was 20 days (range,
7-32 days) when only data for 10 patients who had
eutropenia at the initiation of the preparative regi-
ens were analyzed. In the remaining 66 patients, this
alue was 8 days (range, 0-18 days). A peripheral
eutrophil count 0.1  109/L was observed in 43
atients, with a duration of 1 day (range, 0-21 days).
Of the 74 patients with primary engraftment, 32
43 %) developed grade II to IV acute GVHD on a
edian of day 51 (range, 13-90 days). Acute GVHD
ccurred within 30 days of transplantation in 8 pa-
ients.
ummary of Corticosteroid Use
Forty-one patients were given methylpred-
isolone while they were receiving ATG. Another 18
atients received corticosteroid within 30 days of
ransplantation for the treatment of engraftment syn-
rome (n  6), acute GVHD (n  5), tumor fever
n  1), progression of Behc¸et disease (n  1), brain
dema due to brain metastasis of tumor (n 1), serum
isease due to ATG (n  1), or other causes (n  3).
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6eutropenic Fever
Neutropenic fever developed in 29 (38%) of the
6 patients, with a time interval between the onset of
eutropenia and fever of 7 days (range, 1-13 days).
eﬁned causes of fever are shown in Table 2.
Six patients developed bacteremia during neutro-
enia. Febrile episodes occurred in 5 of these 6 pa-
ients, and the other patient developed a fever after
eutrophil recovery. This patient was excluded from
he cases of patients who had presented a neutropenic
ever caused by bacteremia.
All of the 29 patients with neutropenic fever re-
eived empiric intravenous antibiotics, and 20 patients
esponded. Intravenous amphotericin B was added
mpirically to 3 patients. The probable causes of an-
ibiotic-resistant fevers were as follows: refractory
acteremia (n  4), engraftment syndrome (n  2),
se of ATG plus tumor fever (n  1), and unknown
n  2).
We found that the presence of neutropenic fever
ad no effect on ultimate mortality that included any
ause of death within 30 and 100 days (Table 3).
dditionally, the median follow-up duration was 13.7
able 2. Causes of Neutropenic Fever (n  29)
Variable n
efined causes 20
Bacteremia 5
Engraftment syndrome 4
ATG and tumor fever 1
ATG 10
ndefined causes 9
TG indicates antithymocyte globulin.
able 3. Clinical Characteristics of Patients with Neutropenic Fever an
Variable
ackground
Age, y, median (range)
Primary diseases (hematologic malignancies/others)
Use of antithymocyte globulin (yes/no)
Neutropenia on day 11 (yes/no)
Number of nadir neutrophils, median (range)
Duration of neutropenia, (d), median (range)
Presence of neutropenia 0.1  109/L‡ (yes/no)
Risk of transplantation (high/low)
Diarrhea (yes/no)
Use of steroid (other than ATG) (yes/no)
utcome
Documented bacterial infection within 30 days (yes/no)
Mortality§
Within 30 d
Within 100 d
P values were calculated with univariate analyses by using the Fish
Statistically signiﬁcant.
Presence of a neutrophil count 0.1  109 at any time between d
The mortality includes any causes of death.
8onths (range, 0.27-38.9 months), and the overall
urvival rate after a diagnosis of neutropenic fever was
ot signiﬁcantly different between cases and controls
P  .80; log-rank test; Figure 1).
acterial Infection
Sites of bacterial infection were documented in 15
atients (20%) in the ﬁrst 30 days (Table 4). Twelve of
he 14 patients with bacteremia developed febrile ep-
sodes. All of the 12 febrile patients received intrave-
ous antibiotics, and 6 responded to the empiric use of
ntibiotics. Five patients responded to the second or
hird lines of antibiotics, and 3 of these patients re-
overed from bacteremia after engraftment. The other
atient died of MRSA septicemia on day 8. Two
atients remained afebrile at the diagnosis of bactere-
ia. After a diagnosis was established, we initiated
ancomycin and gentamicin in 1 patient, and the other
ontinued to receive oral ciproﬂoxacin. These 2 pa-
ients improved after the removal of an inserted cath-
ter or neutrophil recovery. One patient with pneu-
onia responded to empiric antibiotics. One patient
ith urinary tract infection showed no response to
ntibiotics and died of systemic infection after the
oncomitant use of steroids for acute GVHD on day
6. Thus, the mortality rate related to early bacterial
nfection after RIST was 1.3% (1/76) within 30 days
fter transplantation.
Gram-positive organisms were cultured in 9 pa-
ients. The pathogens are shown in Table 4. Eight
atients were diagnosed as presenting BSI according
o criterion 2a. In our study, all 8 patients presented
2 blood positive cultures drawn at different times.
ram-negative organisms were cultured from 7 pa-
ols
ts with Neutropenic Fever
(n  29)
Controls
(n  47) P Value*
49 (14-67) 51 (4-65) .97
25/4 33/14 .17
16/13 25/22 .99
7/22 3/44 .037†
60 (0-360) 100 (0-560) .006†
11 (5-26) 7 (0-32) .0001†
22/7 21/26 .0094†
17/12 14/33 .017†
15/14 13/34 .05†
7/22 12/35 .99
8/21 7/40 .24
1 0 .38
4 5 .72
t test and the Mann-Whitney test.
1 and day 30 after RIST.d Contr
Patien
er exac
ay 1
t
g
t
S
n
ﬂ
m
w
r
f
t
t
n
t
a
t
a
c
a
w
u
w
r
c
t
m
0
O
t
w
N
t
s
t
d
e
t
d
w
t
R
t
n
a
s
1
R
1
1
1
f
R
t
b
f
i
p
t
s
(
D
h
T
C
G
G
*
Neutropenic Fever after Reduced-Intensity SCT
Bients, and the pathogens are shown in Table 4. Four
ram-negative strains indicative of multidrug resis-
ance were observed in 4 patients: 3 isolates of
tenotrophomonas maltophilia and 1 isolate of Pseudomo-
as aeruginosa. All of these organisms were sensitive to
uoroquinolones. Three patients developed bactere-
ia caused by ﬂuoroquinolone-sensitive organisms
hile they received prophylaxis.
Bacteremia developed during the neutropenic pe-
iod in 8 of the 14 patients. Of these 8 patients, 6 were
ebrile at the diagnosis of bacteremia, and 1 responded
o the empiric administration of antibiotics. Among
he other 6 patients who developed bacteremia after
eutrophil recovery, all were febrile, and 5 responded
o antibiotics. In the 4 patients with catheter-associ-
ted bacteremia, the fever subsided after removal of
he inserted catheters with the use of appropriate
ntibiotics. Causative organisms were as follows: Ba-
illus species (n  1), Staphylococcus epidermidis (n  2),
nd Serratia species (n  1).
We found that the presence of bacterial infection
ithin the ﬁrst 30 days after RIST had no effect on
ltimate mortality, which included any cause of death
ithin 30 and 100 days (Table 5). The overall survival
ate after the diagnosis of bacteremia was not signiﬁ-
antly different between patients with bacterial infec-
ion and controls (P  .79; log-rank test) with a
edian follow-up duration of 13.7 months (range,
.27-38.9 months; Figure 2).
ther Infectious Complications
Cytomegalovirus antigenemia developed in 12 pa-
ients within 30 days after transplantation, and all
ere successfully treated with preemptive ganciclovir.
one of the patients developed invasive fungal infec-
ions within 30 days after transplantation.
Diarrhea was observed in 5 and 28 patients, re-
pectively, during neutropenia and within 30 days af-
er transplantation. The estimated primary causes of
Figure 1. Overall survival after a diagnosis of neutropenic fever.iarrhea were acute GVHD (n 5), RRT (n 5), and †
B&MTngraftment syndrome (n  5). Clostridium difﬁcile
oxin A was positive in 5 patients, but no suspected
iagnosis was made in the remaining 8 patients. There
as no signiﬁcant association between bacterial infec-
ions and diarrhea (P  .77).
isk Factors for Neutropenic Fever
The patients’ characteristics were compared be-
ween those with and without neutropenic fever. Sig-
iﬁcant risk factors for neutropenic fever by univariate
nalysis are shown in Table 3. Multivariate analysis
howed that presence of a neutrophil count 0.1 
09/L at any time between day 11 and day 30 after
IST (P  .026; 95% conﬁdence interval [CI], 1.20-
6.15), duration of neutropenia (P  .019; 95% CI,
.02-1.24), and diarrhea (P  .016; 95% CI, 1.33-
5.14) were independent risk factors for neutropenic
ever (Table 6).
isk Factors of Documented Bacterial Infections
The patients’ characteristics were compared be-
ween those with and without bacterial infections (Ta-
le 5). None of the variables was a signiﬁcant risk
actor in the univariate analysis. However, a multivar-
ate analysis with logistic regression showed that the
resence of neutropenia at the beginning of prepara-
ive regimens (P  .026; 95% CI, 1.25-35.1) was the
ole independent risk factor for bacterial infections
Table 6).
ISCUSSION
During the ﬁrst few months after transplantation,
ematopoietic SCT (HSCT) recipients carry obvious
able 4. Bacterial Infections (n  15)
Variable n
linical presentation 15*
Bacteremia 13*
Bacteremia and pneumonia 1*
Urinary tract infection 1*
ram-positive organisms 9*
Staphylococcus epidermidis 5†
Bacillus species 3†
MRSA 1†
S. captis 1†
Gram-positive rods 1†
ram-negative organisms 7*
Acinetobacter species 3†
Serratia species 3†
Stenotrophomonas maltophilia 3†
Pseudomonas aeruginosa 2†
Klebsiella species 1†
Escherichia coli 1†
Gardnerella species 1†
Number of patients.
Number of positive cultures.
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7isks for infections [21]. Most physicians believe that
IST is associated with less infection because re-
uced-intensity preparative regimens are less myelo-
blative, leading to a shorter duration of neutropenia
nd less damage to mucosal barriers. However, no
etailed data are currently available to conﬁrm this.
Slavin et al. [6] reported that 25 of 26 recipients of
imilar ﬂudarabine/busulfan-based regimens devel-
ped neutropenia 0.5  109/L, and 8 had neutro-
enia below 0.1 109/L. Considering that life-threat-
ning bacterial infection occurs most often at
eutrophil counts 0.1  109/L in the setting of
onventional allogeneic HSCT [22], RIST might pose
risk for infections. In our study, neutropenia0.5
09/L was observed in essentially all patients, with a
edian duration of 9 days, and neutropenia 0.1 
able 5. Clinical Characteristics of Patients with Bacterial Infections an
Variable
P
ackground
Age, y, median (range)
Primary diseases (hematologic malignancies/others)
Use of antithymocyte globulin (yes/no)
Neutropenia on day 11 (yes/no)
Number of nadir neutrophils, median (range)
Duration of neutropenia, d, median (range)
Presence of neutropenia 0.1  109/L (yes/no)†
Risk of transplantation (high/low)
Diarrhea (yes/no)
Use of steroid (other than ATG) (yes/no)
Central catheters (yes/no)
Peripheral catheters (yes/no)
utcome
Mortality‡
Within 30 d
Within 100 d
P values were calculated with univariate analyses by using the Fish
Presence of a neutrophil count 0.1  109 at any time between d
The mortality includes any causes of death.Figure 2. Overall survival after a diagnosis of bacteremia.
009/L was observed in 56% of the patients, with a
edian duration of 1 day. Thus, neutropenia is still a
igniﬁcant problem in our RIST procedure.
Although it is widely believed that infection is the
rimary cause of febrile neutropenia, a variety of non-
nfectious causes such as drugs, primary diseases,
VHD, and cytokine dysregulation associated with
ngraftment can cause a febrile episode during the
eutropenic period. All of these disorders require in-
ividualized approaches. In our study, approximately
0% of the recipients undergoing RIST developed
ebrile neutropenia, which remains a signiﬁcant prob-
em after RIST, although this is far less than the
eported incidence of 90% after conventional alloge-
rols
with Bacterial Infections
(n  15)
Controls
(n  61) P Value*
53 (16-67) 48 (4-65) .31
13/2 45/16 .50
7/8 34/27 .57
4/11 6/55 .10
100 (0-360) 80 (0-560) .65
9 (2-23) 9 (0-32) .37
7/8 36/25 .40
7/8 24/37 .77
6/9 22/39 .77
6/9 13/48 .18
15/0 56/5 .58
5/10 16/45 .75
1 0 .38
2 7 .99
t test and the Mann-Whitney test.
1 and day 30 after RIST.
able 6. Multivariate Analysis of Risk Factors for Neutropenic Fever
nd Bacterial Infection
Variable
Neutropenic
Fever
(n  29)
Bacterial
Infections
(n  15)
ge — .116 (.99-1.08)
eutropenia on day 11 — .026 (1.25-35.1)†
uration of neutropenia .019 (1.02-1.24)† —
resence of neutropenia
0.1  109/L‡ .026 (1.20-16.15)† .071 (.068-1.117)
isk of transplantation .088 (.86-8.79) —
iarrhea .016 (1.33-15.14)† —
ata are P value (95% conﬁdence interval).
Factors with a P value of .25 in the univariate analysis, except for
those that were considered to be strongly associated with another
variable, were entered into the multiple logistic regression analysis.
Statistically signiﬁcant.
Presence of a neutrophil count 0.1  109/L at any time betweend Cont
atients
er exac
ay 1day 11 and day 30 after RIST.
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Neutropenic Fever after Reduced-Intensity SCT
Beic HSCT [23]. We found that neutropenic fever
ould be attributed to noninfectious causes in 16 of
he 29 patients with febrile neutropenia. Fifteen pa-
ients (20%) had conﬁrmed evidence of documented
nfection within a month after transplantation. Thus,
e also conﬁrmed that the risk of bacterial infection
as predominant in the early period after RIST, as
eported by Junghanss et al. [11]. They reported that
% and 27% of RIST recipients developed bacteremia
ithin 30 and 100 days of transplantation, respec-
ively, and that neutropenia, which was deﬁned as an
bsolute neutrophil count 0.1  109/L, was ob-
erved within a median of 0 days (range, 0-11 days)
11]. They concluded that neutropenia was an inde-
endent risk factor for early bacterial infection. Al-
hough there were considerable differences in the
ransplantation procedures between their study and
urs, the results still suggested that bacterial infection
s a signiﬁcant early complication after RIST. The
igher prevalence of bacterial infections in our study
opulation reﬂected that our preparative regimen was
ore myeloablative compared with the regimen used
y Junghanss et al. [11].
In this study, causative gram-positive bacteria in-
luded S. epidermidis (n  5), Bacillus species (n  3),
nd MRSA (n  1). Wisplinghoff et al. [24] reported
hat secondary BSI most often originated from intra-
enous catheters and occurred in 24% of patients with
neutrophil count 1.0  109/L. The high incidence
f S. epidermidis infection suggests that skin damage
ue to an indwelling central venous catheter could be
he main portal of entry in recipients of RIST, as well
s in conventional HSCT [25]. Because regimen-re-
ated toxicities are mild in RIST and most recipients
an continue oral intake during conditioning and sub-
equent transplantation [26], it may be useful to avoid
lacing central lines in recipients of RIST.
Gram-negative bacteria are the most virulent bac-
erial pathogens in neutropenia. In this study, 7 pa-
ients developed gram-negative bacteremia, and all of
hese patients recovered with neutrophil recovery, in-
ravenous administration of antibiotics, or both. Four
atients had diarrhea at the diagnosis of bacteremia,
ut the remaining 3 showed no evidence of gastroin-
estinal damage. Although gram-negative bacteria
sually invade the bloodstream through damaged gas-
rointestinal mucosa, skin breakdown and venous
atheters might also be possible routes of entry in
IST recipients. Another important ﬁnding of this
tudy was that some causative gram-negative bacteria
ere resistant to multidrugs. Three patients did not
espond to empiric antibiotic therapy. Causative or-
anisms in these 3 patients were Stenotrophomonas mal-
ophilia, Serratia species, Escherichia coli, P. aeruginosa,
nd Acinetobacter species.
We used ﬂuoroquinolones as prophylactic antibi-
tics in RIST, as well as conventional HSCT. It has
B&MTeen reported that although antibacterial prophylaxis
ith ﬂuoroquinolones has reduced the frequency of
ram-negative bacteremia, it has not contributed to
he reduction of infection-related mortality [27].
oreover, the evolution of resistance to ﬂuoroquino-
ones in coagulase-negative staphylococci and E. coli
as been reported [28]. On the basis of these ﬁndings,
he Centers for Disease Control and Prevention
uidelines recommended that the routine use of anti-
iotic prophylaxis should be avoided [29]. We ana-
yzed risk factors for documented bacterial infection
o establish a suitable individualized management of
nfectious complications according to the risk factors.
ur data suggest that the duration of neutropenia and
he presence of neutropenia at the beginning of pre-
arative regimens are independent risk factors for
eutropenic fever and bacterial infection, respectively,
y multivariate analysis (Table 6). Risk of transplan-
ation was not an independent risk factor on multivar-
ate analysis. However, considering that risk of trans-
lantation and neutropenia were closely associated, we
an safely say that high-risk patients have a high prob-
bility for developing bacteremia and neutropenic fe-
ers. These ﬁndings suggest that routine prophylaxis
hould be individualized according to the risk of early
acterial infection.
Our study has several limitations. First, this is a
etrospective study, and the rate of febrile episodes
ould be inﬂuenced by the variable use of antipyretic
gents. Second, we could not compare the rate of
eutropenic fever and bacterial infections with con-
rols receiving myeloablative SCT. Third, a central
enous catheter was inserted in 93% of the patients;
herefore, we could not evaluate the contribution of
atheter use to the development of bacteremia. There-
ore, further studies are needed to evaluate the rate of
eutropenic fever and bacterial infections in patients
ithout the use of a central venous catheter.
In conclusion, we found that bacterial infection is
till a signiﬁcant problem after RIST, as well as con-
entional allogeneic HSCT. Our data demonstrated
hat the treatment of bacterial infections within the
arly period after RIST requires individualized man-
gement according to the deﬁned risk. It may be
eneﬁcial to avoid the routine use of a central venous
atheter in recipients of RIST, which could reduce the
ncidence of early gram-positive bacteremia, although
his should be conﬁrmed in a future prospective study.
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